Phenobarbital Treatment in a Patient with Resistant Alcohol Withdrawal Syndrome
- 1 July 2009
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 29 (7) , 875-878
Abstract
Alcohol withdrawal syndrome (AWS) is a major cause of morbidity and mortality in the acute care setting. We describe a 28‐year‐old man who was brought to the emergency department with a new‐onset seizure and clinical signs and symptoms consistent with advanced delirium tremens. A symptom‐triggered intensive care unit treatment protocol consisting of a benzodiazepine and antiadrenergic agents was started. The manifestations of delirium tremens persisted with titration of a lorazepam infusion in excess of 40 mg/hour. Intravenous phenobarbital was administered in escalating doses of 65 mg followed by 130 mg 15 minutes later, resulting in control of severe agitation in the face of benzodiazepine resistance. Subsequent scheduled phenobarbital administration allowed for a successful and orderly weaning of the continuous benzodiazepine infusion and adjunctive agents used in AWS management. With continued clearing of consciousness, the patient was successfully discharged. The administration of phenobarbital in this patient allowed improved symptom control, minimized the potential for propylene glycol toxicity, was not associated with respiratory depression, and facilitated successful weaning of benzodiazepines. Barbiturates offer a mechanism of action that is different from that of benzodiazepines. Although the cornerstone of treatment for AWS remains benzodiazepines, this case highlights the potential utility of phenobarbital in patients with resistant AWS.Keywords
This publication has 16 references indexed in Scilit:
- A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens*Critical Care Medicine, 2007
- Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for SedationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Management of Alcohol Withdrawal DeliriumAn Evidence-Based Practice GuidelineArchives of internal medicine (1960), 2004
- Management of Drug and Alcohol WithdrawalNew England Journal of Medicine, 2003
- Withdrawal from Chronic Intermittent Ethanol Treatment Changes Subunit Composition, Reduces Synaptic Function, and Decreases Behavioral Responses to Positive Allosteric Modulators of GABAA ReceptorsMolecular Pharmacology, 2003
- The Richmond Agitation–Sedation Scale: Validity and Reliability in Adult Intensive Care Unit PatientsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Evaluation of delirium in critically ill patients: Validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)Critical Care Medicine, 2001
- Pharmacokinetic Dosing of Phenobarbital in the Treatment of Alcohol Withdrawal SyndromeSouthern Medical Journal, 1991
- Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar)British Journal of Addiction, 1989
- Intravenous phenobarbital for alcohol withdrawal and convulsionsAnnals of Emergency Medicine, 1987